Inovio Pharmaceuticals, Inc.
INO
$1.34
$0.021.52%
NASDAQ
| 06/30/2026 | 03/31/2026 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -23.05% | 37.12% | |||
| Gross Profit | 23.05% | -37.12% | |||
| SG&A Expenses | -1.04% | 9.21% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -15.15% | 25.60% | |||
| Operating Income | 15.15% | -25.60% | |||
| Income Before Tax | 69.45% | -622.80% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 69.45% | -622.80% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 69.45% | -622.80% | |||
| EBIT | 15.15% | -25.60% | |||
| EBITDA | 15.40% | -26.24% | |||
| EPS Basic | 74.12% | -569.19% | |||
| Normalized Basic EPS | 75.94% | -566.14% | |||
| EPS Diluted | 74.12% | -569.19% | |||
| Normalized Diluted EPS | 75.94% | -566.14% | |||
| Average Basic Shares Outstanding | 18.11% | 11.40% | |||
| Average Diluted Shares Outstanding | 18.11% | 11.40% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||